Jedd D. Wolchok

Research interests

Publications

• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407417

• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  Zurich Open Repository and Archive (University of Zurich) · 2022 · https://doi.org/10.5167/uzh-213514

• Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

  Immunity · 2021 · https://doi.org/10.1016/j.immuni.2021.05.003

• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1910836

• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  Nature Genetics · 2019 · https://doi.org/10.1038/s41588-018-0312-8

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz011

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.77.6385

• Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1716078

• Cancer immunotherapy using checkpoint blockade

  Science · 2018 · https://doi.org/10.1126/science.aar4060

• Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.75.3384

• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

  Cancer Discovery · 2018 · 10.1158/2159-8290.cd-18-0099

• Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.03.018

• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30074-8

• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709684

• T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

  Nature · 2017 · 10.1038/nature22079

• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2015.66.1389

• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0391

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1611299

• RECIST 1.1—Update and clarification: From the RECIST committee

  European Journal of Cancer · 2016 · 10.1016/j.ejca.2016.03.081

• Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.2477

• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  Science Translational Medicine · 2016 · 10.1126/scitranslmed.aad7118

• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

  JAMA · 2016 · 10.1001/jama.2016.4059

• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  Science · 2016 · 10.1126/science.aaf1490

• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00083-2

• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  Science · 2015 · https://doi.org/10.1126/science.aaa1348

• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504030

• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414428

• Immune Checkpoint Blockade in Cancer Therapy

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.59.4358

• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.56.2736

• Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

  Cell · 2015 · 10.1016/j.cell.2015.07.011

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1406498

• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)60958-2

• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  The Journal of Experimental Medicine · 2013 · 10.1084/jem.20130579

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1305133

• Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1302369

• Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1112824

• Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

  Nature Medicine · 2012 · 10.1038/nm.2753

• Antibody therapy of cancer

  Nature reviews. Cancer · 2012 · 10.1038/nrc3236

• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1104621

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-09-1624

Current projects

No projects listed.